150 related articles for article (PubMed ID: 24589079)
21. Cytochrome P450 CYP 2C19*2 Associated with Adverse 1-Year Cardiovascular Events in Patients with Acute Coronary Syndrome.
Wei YQ; Wang DG; Yang H; Cao H
PLoS One; 2015; 10(7):e0132561. PubMed ID: 26147597
[TBL] [Abstract][Full Text] [Related]
22. The impact of genetic polymorphisms of P2Y12, CYP3A5 and CYP2C19 on clopidogrel response variability in Iranian patients.
Namazi S; Kojuri J; Khalili A; Azarpira N
Biochem Pharmacol; 2012 Apr; 83(7):903-8. PubMed ID: 22265638
[TBL] [Abstract][Full Text] [Related]
23. The Impact of CYP2C19 Loss-of-Function Polymorphisms, Clinical, and Demographic Variables on Platelet Response to Clopidogrel Evaluated Using Impedance Aggregometry.
Mărginean A; Bănescu C; Moldovan V; Scridon A; Mărginean M; Bălaşa R; Maier S; Ţăruşi M; Dobreanu M
Clin Appl Thromb Hemost; 2017 Apr; 23(3):255-265. PubMed ID: 26873108
[TBL] [Abstract][Full Text] [Related]
24. Effects of coexisting polymorphisms of CYP2C19 and P2Y12 on clopidogrel responsiveness and clinical outcome in patients with acute coronary syndromes undergoing stent-based coronary intervention.
Tang XF; Zhang JH; Wang J; Han YL; Xu B; Qiao SB; Wu YJ; Chen J; Wu Y; Chen JL; Gao RL; Yang YJ; Yuan JQ
Chin Med J (Engl); 2013 Mar; 126(6):1069-75. PubMed ID: 23506580
[TBL] [Abstract][Full Text] [Related]
25. Effect of high-dose clopidogrel according to CYP2C19*2 genotype in patients undergoing percutaneous coronary intervention- a systematic review and meta-analysis.
Zhang L; Yang J; Zhu X; Wang X; Peng L; Li X; Cheng P; Yin T
Thromb Res; 2015 Mar; 135(3):449-58. PubMed ID: 25511576
[TBL] [Abstract][Full Text] [Related]
26. Point-of-care genetic profiling and/or platelet function testing in acute coronary syndrome.
Collet JP; Kerneis M; Hulot JS; O'Connor SA; Silvain J; Mansencal N; Brugier D; Abtan J; Barthélémy O; Vignalou JB; Payot L; Rousseau H; Vicaut E; Montalescot G;
Thromb Haemost; 2016 Jan; 115(2):382-91. PubMed ID: 26423110
[TBL] [Abstract][Full Text] [Related]
27. Advocating cardiovascular precision medicine with P2Y12 receptor inhibitors.
Winter MP; Grove EL; De Caterina R; Gorog DA; Ahrens I; Geisler T; Gurbel PA; Tantry U; Navarese EP; Siller-Matula JM
Eur Heart J Cardiovasc Pharmacother; 2017 Oct; 3(4):221-234. PubMed ID: 28204303
[TBL] [Abstract][Full Text] [Related]
28. Genetic Determinants of P2Y
Cavallari LH; Obeng AO
Interv Cardiol Clin; 2017 Jan; 6(1):141-149. PubMed ID: 27886818
[TBL] [Abstract][Full Text] [Related]
29. Association of CYP2C19, CYP3A5 and GPIIb/IIIa gene polymorphisms with Aspirin and Clopidogrel Resistance in a cohort of Indian patients with Coronary Artery Disease.
Arya V; Mahajan P; Saraf A; Mohanty A; Sawhney JP; Bhargava M
Int J Lab Hematol; 2015 Dec; 37(6):809-18. PubMed ID: 26264906
[TBL] [Abstract][Full Text] [Related]
30. The impact of gene polymorphism and high on-treatment platelet reactivity on clinical follow-up: outcomes in patients with acute coronary syndrome after drug-eluting stent implantation.
Liang ZY; Han YL; Zhang XL; Li Y; Yan CH; Kang J
EuroIntervention; 2013 Jul; 9(3):316-27. PubMed ID: 23872648
[TBL] [Abstract][Full Text] [Related]
31. Comparison of the effect of CYP2C19 polymorphism on clinical outcome between acute coronary syndrome and stable angina.
Arima Y; Hokimoto S; Akasaka T; Mizobe K; Kaikita K; Oniki K; Nakagawa K; Ogawa H
J Cardiol; 2015 Jun; 65(6):494-500. PubMed ID: 25156215
[TBL] [Abstract][Full Text] [Related]
32. CYP2C19 polymorphisms and coronary heart disease risk factors synergistically impact clopidogrel response variety after percutaneous coronary intervention.
Liu T; Yin T; Li Y; Song LQ; Yu J; Si R; Zhang YM; He Y; Guo WY; Wang HC
Coron Artery Dis; 2014 Aug; 25(5):412-20. PubMed ID: 24608794
[TBL] [Abstract][Full Text] [Related]
33. Genotype Frequencies of CYP2C19, P2Y12 and GPIIIa Polymorphisms in Coronary Heart Disease Patients of Han Ethnicity, and Their Impact on Clopidogrel Responsiveness.
Ou W; He Y; Li A; Liu B; Jin L
Int Heart J; 2016 Sep; 57(5):586-92. PubMed ID: 27488401
[TBL] [Abstract][Full Text] [Related]
34. Genetic Polymorphism of CYP2C19 and Inhibitory Effects of Ticagrelor and Clopidogrel Towards Post-Percutaneous Coronary Intervention (PCI) Platelet Aggregation in Patients with Acute Coronary Syndromes.
Dong P; Yang X; Bian S
Med Sci Monit; 2016 Dec; 22():4929-4936. PubMed ID: 27977637
[TBL] [Abstract][Full Text] [Related]
35. CYP2C19 genotyping combined with on-clopidogrel platelet reactivity in predicting major adverse cardiovascular events in Chinese patients with percutaneous coronary intervention.
Tang XF; Han YL; Zhang JH; Wang J; Yao Y; He C; Xu B; Gao Z; Qiao SB; Chen J; Wu Y; Chen JL; Gao RL; Yang YJ; Yuan JQ
Thromb Res; 2016 Nov; 147():108-114. PubMed ID: 27728892
[TBL] [Abstract][Full Text] [Related]
36. Association Between CYP2C19 Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic Attack.
Wang Y; Zhao X; Lin J; Li H; Johnston SC; Lin Y; Pan Y; Liu L; Wang D; Wang C; Meng X; Xu J; Wang Y;
JAMA; 2016 Jul; 316(1):70-8. PubMed ID: 27348249
[TBL] [Abstract][Full Text] [Related]
37. Coexisting polymorphisms of P2Y12 and CYP2C19 genes as a risk factor for persistent platelet activation with clopidogrel.
Malek LA; Kisiel B; Spiewak M; Grabowski M; Filipiak KJ; Kostrzewa G; Huczek Z; Ploski R; Opolski G
Circ J; 2008 Jul; 72(7):1165-9. PubMed ID: 18577829
[TBL] [Abstract][Full Text] [Related]
38. Impact of CYP2C19 Metabolizer Status on Patients With ACS Treated With Prasugrel Versus Clopidogrel.
Doll JA; Neely ML; Roe MT; Armstrong PW; White HD; Prabhakaran D; Winters KJ; Duvvuru S; Sundseth SS; Jakubowski JA; Gurbel PA; Bhatt DL; Ohman EM; Fox KAA;
J Am Coll Cardiol; 2016 Mar; 67(8):936-947. PubMed ID: 26916483
[TBL] [Abstract][Full Text] [Related]
39. Genotype-guided treatment of oral P2Y
Claassens DM; Ten Berg JM
Pharmacogenomics; 2020 Jan; 21(2):83-86. PubMed ID: 31957547
[No Abstract] [Full Text] [Related]
40. Decreased platelet responsiveness to clopidogrel correlates with CYP2C19 and PON1 polymorphisms in atherosclerotic patients.
Marchini JF; Pinto MR; Novaes GC; Badran AV; Pavão RB; Figueiredo GL; Lago IM; Lima-Filho MO; Lemos DC; Tonani M; Antloga CM; Oliveira L; Lorenzi JC; Marin-Neto JA
Braz J Med Biol Res; 2017 Jan; 50(1):e5660. PubMed ID: 28076455
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]